News

FDA warns of possible dosing errors with Zerbaxa


 

References

Confusion about the strength of the antibacterial drug Zerbaxa could potentially lead to dosage errors, the Food and Drug Administration cautioned in a May 20 announcement.

The label for Zerbaxa was approved with a strength that reflects each individual active ingredient, although the product is dosed based on the sum of these ingredients, which has led to at least seven cases of medication error, the FDA said.

“In some cases, this led to administration of 50% more drug than was prescribed,” the agency said in its statement.

To prevent future confusion, the FDA has revised the labeling to show the sum of the two active ingredients, ceftolozane and tazobactam. The strength will now be listed as 1.5 g, equivalent to 1 g of ceftolozane and 0.5 g tazobactam. This labeling is consistent with other beta-lactam/beta-lactamase medications that list drug strength as the sum of the two active ingredients, the FDA said.

Zerbaxa is approved to treat complicated urinary tract infections and intra-abdominal infections in combination with metronidazole.

No adverse events were reported in the seven cases that were evaluated. Patients and providers can report serious side effects, adverse events, and medication dosage errors to the FDA’s MedWatch program.

mrajaraman@frontlinemedcom.com

Recommended Reading

ILC: Direct antivirals safely clear HCV despite ESRD
MDedge Family Medicine
Norovirus outbreak likely caused by swimming in infected waters
MDedge Family Medicine
DDW: Significant worker productivity gains with newer hepatitis C drugs
MDedge Family Medicine
DDW: Menopausal hormone therapy increases major GI bleed risk
MDedge Family Medicine
ATS: High-dose nitric oxide looks promising for infants with bronchiolitis
MDedge Family Medicine
DDW: HBV, tuberculosis reactivations rare in IBD patients on biologic therapy
MDedge Family Medicine
DDW: Recurrent C. difficile infections take heavy toll on IBD patients
MDedge Family Medicine
Food recalls highlight risk of listeriosis
MDedge Family Medicine
CDC: Tdap vaccine coverage during pregnancy is low
MDedge Family Medicine
PAS: Use high-dose acyclovir to treat HSV-infected infants
MDedge Family Medicine